Investigational Drug Information for SKLB1028
✉ Email this page to a colleague
What is the drug development status for SKLB1028?
SKLB1028 is an investigational drug.
There have been 9 clinical trials for SKLB1028.
The most recent clinical trial was a Phase 1 trial, which was initiated on March 24th 2021.
The most common disease conditions in clinical trials are Leukemia, Myeloid, Acute, Leukemia, Myeloid, and Leukemia. The leading clinical trial sponsors are CSPC ZhongQi Pharmaceutical Technology Co., Ltd. and [disabled in preview].
There is one US patent protecting this investigational drug and ten international patents.
Summary for SKLB1028
| US Patents | 1 |
| International Patents | 10 |
| US Patent Applications | 13 |
| WIPO Patent Applications | 13 |
| Japanese Patent Applications | 3 |
| Clinical Trial Progress | Phase 1 (2021-03-24) |
| Vendors | 28 |
Recent Clinical Trials for SKLB1028
| Title | Sponsor | Phase |
|---|---|---|
| A Study of SKLB1028 in Patients With Advanced Solid Tumor | CSPC ZhongQi Pharmaceutical Technology Co., Ltd. | Phase 1 |
| SKLB1028, Daunorubicin, and Cytarabine in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia (AML) | CSPC ZhongQi Pharmaceutical Technology Co., Ltd. | Phase 1/Phase 2 |
| A Mass Balance and Biotransformation Study of [14C]SKLB1028 in Chinese Healthy Male Subjects | CSPC ZhongQi Pharmaceutical Technology Co., Ltd. | Phase 1 |
Clinical Trial Summary for SKLB1028
Top disease conditions for SKLB1028
Top clinical trial sponsors for SKLB1028
US Patents for SKLB1028
| Drugname | Patent Number | Patent Title | Patent Assignee | Estimated Expiration |
|---|---|---|---|---|
| SKLB1028 | ⤷ Subscribe | Arylamino purine derivatives, preparation method and pharmaceutical use thereof | CSPC Zhongqi Pharmaceutical Technology (Shijiazhuang) Co., Ltd. (Shijiazhuang, Hebei Province, CN) Sichuan University (Chengdu, Sichuan Province, CN) | ⤷ Subscribe |
| >Drugname | >Patent Number | >Patent Title | >Patent Assignee | >Estimated Expiration |
International Patents for SKLB1028
| Drugname | Country | Document Number | Estimated Expiration | Related US Patent |
|---|---|---|---|---|
| SKLB1028 | China | CN102260263 | 2030-05-26 | ⤷ Subscribe |
| SKLB1028 | China | CN103003278 | 2030-05-26 | ⤷ Subscribe |
| SKLB1028 | China | CN105832740 | 2030-05-26 | ⤷ Subscribe |
| SKLB1028 | European Patent Office | EP2578584 | 2030-05-26 | ⤷ Subscribe |
| SKLB1028 | Spain | ES2814257 | 2030-05-26 | ⤷ Subscribe |
| >Drugname | >Country | >Document Number | >Estimated Expiration | >Related US Patent |
